Home
|
About us
|
News & Articles
|
Events
|
Media Info
|
Editorial
|
Subscribe
|
Archive
|
Contact Us
Company News ...
SUPPORTING THE INDUSTRY THROUGH COMMUNICATION
Newsletter sign-up
Danish ScanBalt
Natoli Engineering
Swiss WorldCargo
BioWin
Lyofal
BMG LABTECH
Randox Pharma
Phage Consultants
Oslo Cancer Cluster
Woodley equipment
Bobst Group
Marken
Biotec Services
Vetter
Hyglos
Burkert
One Nucleus
BASi Inc
Novozymes
Domino
Ludger
MPI Research
Vindon
Stirling Ultracold
Julabo
Ambry Genetics Announces Certified Service Provider Status for Agilent Microarrays ALISO VIEJO, CA, Sept 14, 2009 / b3c newswire / – Ambry Genetics announced today that they have completed certification to become an Agilent Certified Service Provider on the Agilent microarray platform. The initial certification is for Comparative Genomic Hybridization (aCGH) which is an application used by researchers to discover and detect genomic copy number variations within specific genomes. The Certified Service Provider program comprises a select list of strategic organizations that pass a rigorous assessment to use Agilent's microarray platform. The program combines the provider's focused expertise with the complete Agilent microarray workflow to create specialized services or complete genomic research solutions. “We are thrilled to be the first Agilent Certified Service Provider on the West Coast of the United States,” said Ardy Arianpour, Director of Business Development, Pharmaceutical Services at Ambry Genetics. “Our Pharmaceutical, Biotech, and Academic customers will be able to receive the highest quality results and service with the CSP stamp of approval. This accomplishment continues to demonstrate Ambry Genetics’ dedication to our customers and the genomics services industry.” “Array comparative genomic hybridization has become the approach of choice in research settings to comprehensively identify chromosomal imbalances throughout the genome,” added Dr. Aaron Elliott, R&D Scientist, Ambry Genetics. “Agilent’s wide variety of catalog arrays combined with a cost effective custom design capability available through Agilent’s eArray software allows us to provide our researchers with highly sensitive genome-wide scans at varying resolutions. Our CSP status further ensures our researchers that they are getting the best quality service available.” Link to the news release About Ambry Genetics - www.ambrygen.com Ambry Genetics is a CAP-accredited, GLP-compliant, CLIA-certified commercial clinical laboratory headquartered in Aliso Viejo, California. Since the company’s inception in 2000, it has become a leader in providing genetic services focused on clinical diagnostics, pharmacogenomics and research support services. Ambry has built a solid reputation for unparalleled service, and has been at the forefront of applying new technologies to the clinical molecular diagnostics market and advancements in disease research. To learn more about testing and services available through Ambry, visit www.ambrygen.com. About Agilent Technologies - www.agilent.com Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company’s 18,000 employees serve customers in more than 110 countries. Agilent had net revenues of $5.8 billion in fiscal 2008. Contact: Jeff Owen phone +1-949-900-5542 e-mail: jowen@ambrygen.com
Evotec Achieves Milestone in Medicinal Chemistry Collaboration with Ono Pharmaceutical Co., Ltd. - Evotec receives milestone from Ono for the progression of novel protease inhibitors into lead optimisation - Hamburg, Germany / Abingdon, UK – 14 December 2009: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that it has received a milestone payment from Ono Pharmaceutical Co., Ltd. (Ono) from its research collaboration aimed at identifying novel inhibitors for a protease target. The milestone is received for the progression of the medicinal chemistry collaboration into lead optimisation. The programme success validates again the strength of Evotec’s Fragment Based Drug Discovery platform, EVOlutionTM, along with its integrated drug discovery capabilities, including biology, medicinal chemistry, structure based drug design and in vitro pharmacology. Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “We are delighted to have achieved this important milestone with Ono and once again to demonstrate the value that we bring to our partnership with them. The success of this project is a testament to the strong partnership between our two companies and we look forward to continuing working closely with our colleagues at Ono both on this programme as it progresses to the clinic as quickly as possible and also on our recently initiated collaboration on a second target as proactively as possible.” “We have a high regard for Evotec's drug discovery expertise and the capabilities and technologies used in progressing this collaboration. The achievement of this milestone further validates our strategy to work with the best collaborators in the industry. We look forward to reaching additional milestones together as our programmes progress” said Kazuhito Kawabata, Ph.D., Managing Director, Head of Research Headquarters and Director of Minase Research Institute at Ono. Evotec and Ono are also collaborating on a second target, an ion channel, for which Ono will access Evotec’s ion channel drug discovery platform and expertise. For this second programme Evotec will receive further research funding and milestone payments. About Evotec AG Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has built substantial drug discovery expertise and an industrialized platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, and inflammation. Leveraging these skills and expertise the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in clinical development and a series of preclinical compounds and development partnerships, including for example a strategic alliance with Roche for the EVT 100 compound family, subtype selective NMDA receptor antagonists for use in treatment-resistant depression. For additional information please go to www.evotec.com. About Ono Pharmaceutical Co., Ltd. In keeping with its philosophy of “Dedicated to Man’s Fight against Disease and Pain,” Ono has always striven to achieve its goal of serving as an R&D-oriented global speciality pharmaceuticals, aiming to develop innovative and globally recognized drugs. To do this, Ono has been engaged in drug discovery research based on accumulated technologies and know-how – in areas where our strengths can be fully exploited (i.e. bioactive lipid agonists and enzyme inhibitors such as proteases and kinases). In addition, modulators of membrane transport system such as ion-channels and transporters as well as biotechnology based medicines are also the areas of our focus where we drive forward our research effectively deploying our know-how from neuroscience research and our gene assets together with the latest information acquired from global research institutions on drug discovery targets and the cutting-edge drug discovery technologies that biopharmaceutical companies can offer. Forward-looking statements Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about our expectations and assumptions concerning regulatory, clinical and business strategies, the progress of our clinical development programmes and timing of the results of our clinical trials, strategic collaborations and management's plans, objectives and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: risks that the Company may be unable to reduce its cash burn through recent restructuring and cost containment measures and may not recognize the results of such measures within the expected timeframe; risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured; the risk that we will not achieve the anticipated benefits of our collaborations, partnerships and acquisitions in the timeframes expected, or at all; risks relating to our ability to advance the development of product candidates currently in the pipeline or in clinical trials; our inability to further identify, develop and achieve commercial success for new products and technologies; the risk that competing products may be more successful; our inability to interest potential partners in our technologies and products; our inability to achieve commercial success for our products and technologies; our inability to protect our intellectual property and the cost of enforcing or defending our intellectual property rights; our failure to comply with regulations relating to our products and product candidates, including FDA requirements; the risk that the FDA may interpret the results of our studies differently than we have; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully secure regulatory approval of and market our drug candidates; and risks of new, changing and competitive technologies and regulations in the U.S. and internationally. The list of risks above is not exhaustive. Our most recent Annual Report on Form 20-F, filed with the Securities and Exchange Commission, and other documents filed with, or furnished to the Securities and Exchange Commission, contain additional factors that could impact our businesses and financial performance. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
Recipharm announces its intention to acquire Cobra Biomanufacturing Move will more than double Recipharm’s biologics business Recipharm AB, one of the leading contract pharmaceutical development and manufacturing organisations (CDMO), announces today its intention to acquire Cobra Biomanufacturing plc, a leading UK-based, cGMP compliant contract manufacturer of biopharmaceuticals. This move will considerably broaden Recipharm’s biologics offering whilst providing access to new markets and technologies including the production of proteins, viruses, DNA and cells for use in pre-clinical through to Phase II clinical trials. With facilities located in Oxford and Keele (UK), Cobra Biomanufacturing is an established provider of DNA for gene therapy. The company has the capability to utilise the MaxXpress maximum protein expression system, harnessing the power of UCOE technology, to deliver high productivity cell lines and strains and reduced manufacturing costs for its clients. Cobra has also established a significant I.P. portfolio around its own oral vaccine technology, ORT-VAC, based on their patented high plasmid maintenance technology. The ORT-VAC technology has the potential to deliver a wide range of vaccines that would be taken orally. The acquisition of Cobra Biomanufacturing will form an integral part of Recipharm’s strategic goal to increase its footprint in biologics and offer higher volumes of GMP production together with a wider range of services. The move is set to more than double the size of Recipharm’s biologics business Long-term, Recipharm plans to provide a full suite of ‘one-stop shop’ biologics capabilities, expanding on its current biomanufacturing services and its ability to fill and finish active pharmaceutical ingredients. Recipharm intends to both retain Cobra Biomanufacturing’s existing expertise and will actively recruit additional personnel to bolster its newly combined biologics business. Commenting on the news, Thomas Eldered, CEO and managing director of Recipharm, said, “Our intended acquisition of Cobra Biomanufactuing is yet another example of our stated goal to develop world-class development and manufacturing solutions for the biopharmaceutical industry. This operation will run alongside our existing biologics facility in Sweden and complements very well our established capabilities in small molecules. This I believe creates a very strong offering, enabling us to further develop our customer base amongst both emerging biotechnology and large pharmaceutical companies.” Commenting on the acquisition, Simon Saxby, CEO of Cobra, said, “The acquisition by Recipharm of Cobra is a welcome and essential step in order for Cobra to be able to provide the long term stability and increased scale needed for our clients. In a combined organisation with Recipharm we will be able to compete very strongly and more effectively in the global biomanufacturing market”. About Recipharm Recipharm is a leading contract development and manufacturing organisation based in Europe. The Company operates nine main manufacturing facilities in Sweden, France, the UK and Switzerland and is headquartered near Stockholm. Recipharm supplies the global pharmaceuticals market with in excess of six hundred different products in multiple dosage forms that include solid dose, granulates and powders, sterile liquids and lyophiles semi solids, beta-lactams, hormones and dry powder inhalers. Website: www.recipharm.com. About Cobra Biomanufacturing Cobra is a leading cGMP compliant contract manufacturer of biopharmaceuticals with over 15 years of experience in producing biopharmaceuticals, including proteins, viruses, DNA and cells for use in pre-clinical to Phase III clinical trials. Cobra has also developed a strong I.P. portfolio around its ORT / ORT-VAC oral vaccine technology. Cobra is headquartered on the Keele Science Park with second manufacturing facility in Oxford. Website: www.cobrabio.com For further information, please contact: Thomas Eldered Tel: + 46 (0)86 02 5211 CEO and Managing Director Recipharm AB Mark Quick Tel: +44 1925 714263 VP Corporate Development Recipharm AB Carl-Johan Spak Tel: +46 (0) 8 602 53 13 VP New Ventures Recipharm AB Kevin Payne or Tristan Jervis De Facto Communications Tel: +44 (0) 207 861 3023/3019 E-mail Tristan Jervis or Kevin Payne t.jervis@defacto.com or k.payne@defacto.com Tristan Jervis Account Director De Facto Communications
Press Release Romaco Group Consolidation of the Italian brands of Romaco Production all located under one roof in Bologna Romaco is consolidating its Italian production in Bologna. The plant in Rastignano has been reorganized and expanded for this purpose. Romaco Srl employs around 110 employees at the production site in Bologna. Karlsruhe/Germany, 03.05.2010. Romaco is combining its two Italian production sites in Rastignano, Bologna. For this purpose the Italian Romaco brands Macofar, Promatic and Unipac were physically consolidated. From now on, Romaco Srl, the Italian subsidiary of the Romaco Group, will be located under one roof and centrally administered. During the lead-up period, the packaging specialist's location in Rastignano had already been comprehensively renovated and expanded. In total, approximately 110 employees have 6,500 square meters at their disposal. The restructuring of the production site did not result in any staff cuts. In fact, the goal of the consolidation is to process the increasing volume of orders within the shortest possible time. With extensive investment and consistent implementation of “lean principles”, Romaco is optimizing its working processes and expanding its production capacity. The primary and secondary packaging of pharmaceutical products and cosmetics are the core activities of the Italian brands of the Romaco Group. Macofar produces machines and full lines for filling liquids and powders, as well as capsules. Promatic has many years of know-how in the development of cartoning machines and case packers. And finally, Unipac has specialized in the filling of semi-solids into tubes. “The consolidation and reorganization of Romaco Srl increases our efficiency and effectiveness as well as our flexibility,” explains Paolo Naldi, Managing Director of Romaco Srl at Rastignano. “The extensive investment in the common location will contribute significantly to improvement of our quality and supply capacity.” Romaco is one of the world's leading providers of machines and facilities for processing and packaging. With sections for processing and packaging, the organization develops technical solutions for the pharmaceutical, cosmetics and food industries. The Romaco Group, based in Karlsruhe (Germany), is part of the exchange-listed U.S. corporation Robbins & Myers, Inc. (Dayton, Ohio). Romaco is represented by a total of seven brands at four European locations in Germany, Switzerland and Italy. Bosspak, Macofar, Noack, Promatic, Siebler and Unipac represent the packaging aspect of the business, while the processing sector is covered by the FrymaKoruma brand. More than 50,000 Romaco machines are currently in use in over 130 countries. About 500 employees look after and supply more than 100 markets worldwide.
PRESS INFORMATION September 7, 2010 BRECON CELEBRATES 30TH ANNIVERSARY WITH STRONG PERFORMANCE Brecon Pharmaceuticals has followed its strong 2009 performance with a record performance in 2010 - the company's 30th anniversary - as clients in the global pharmaceutical and healthcare industries recognise the value and buy into the company's portfolio of commercial packaging and clinical trials services. Recent months have seen Brecon secure several major projects; including the launch of new over-the-counter and prescription drugs, packaging a range of fluid-filled lenses and managing both packaging and logistics for a range of animal health products. In the clinical supplies arena, Brecon has successfully bid for a number of new contracts covering packing of Phase II and III trials supplies, with associated storage and distribution services. Brecon also reports growth in demand for Late Stage Customisation (LSC) solutions and increased call on facilities for storage of controlled drugs, requirements that are being satisfied by continuing investment in facilities and technology at the company's Hay-on-Wye site Brecon business development director Steve Kemp says the sales success "is a reward for our dedication to delivering the most up to date and innovative range of technologies and services so that we can tailor our offering to clients' needs - a policy the company has maintained for every one of its 30 years. It also underlines our commitment to supporting clients' products throughout their life cycle, from early clinical trials to full commercialisation. This frees up pharmaceutical companies to focus on their core competencies of drug development and manufacture, while outsourcing key support functions such as clinical supply, analytical and regulatory services, commercial packaging, and storage and distribution." "It's a strategy that's more relevant than ever in the prevailing economic climate - but it does depend on service partners that are up to the task. Here at Brecon we aim to excel on every front: training, technology facilities and customer service." Kemp adds that as a member of US healthcare services specialist AmerisourceBergen Corporation, Brecon works closely with sister companies to offer co-ordinated global solutions that comply with EU, US and other international legislatures.
Press Release: Biopeople becomes Danish ScanBalt Liaison Office Biopeople today is welcomed as Danish liaison office for ScanBalt BioRegion at a ceremony in Copenhagen. Biopeople is part of the permanent Danish infrastructure for innovation established and co-funded by the Danish Agency for Science, Technology and Innovation and the Danish Council for Technology and Innovation. Biopeople embraces universities, research organisations, and hospitals, the Danish Medicines Agency, industry associations as well as pharma, medtech, medical device, food and biotech companies. Key objectives of the liaison office are to promote the attraction of EU and other investments to regional Danish hubs via collaborations in ScanBalt BioRegion and to strengthen the awareness of Danish competencies and resources around the Baltic Sea. Per Spindler, Director of Biopeople says “With the approval of the EU Baltic Sea Region strategy in 2009 it is increasingly important to collaborate with our neighbours as support to our other national and international efforts. We regard this as an important service to our stakeholders and Denmark needs to play an active role in the shapening of the first EU macro-region, the Baltic Sea Region”. Wolfgang Blank, Chairman of ScanBalt and CEO of BioCon Valley ads “We are happy for the possibility to further integrate Danish competencies into various ScanBalt activities and projects like the EU Baltic Sea Region strategy’s flagship project ScanBalt Health Region. ScanBalt BioRegion is today regarded as a leading example of regional collaboration in the EU and this is another step forward”. For further information please contact Per Spindler at +45 2875 6572 or Wolfgang Blank at +49 171 7610133. For further information on Biopeople, see www.biopeople.dk ScanBalt BioRegion – Life Sciences on Top of Europe. The leading network of clusters, universities, companies and public authorities working within Life sciences and Health to promote the Baltic Sea or Nordic-Baltic Region as a globally competitive green valley and health region. Read more at www.scanbalt.org
For further information, please contact: BioWisdom Jane Reed, Director of Life Sciences Tel: +44 (0)1223 874800 Website: http://www.biowisdom.com Email: info@biowisdom.com PRESS RELEASE For immediate release BIOWISDOM EXTENDS PARTNERSHIP WITH ASTRAZENECA FOR SAFETY INTELLIGENCE PROGRAM October 2010, Cambridge, UK - BioWisdom Ltd (BioWisdom), the market leader in delivering healthcare intelligence to the pharmaceutical industry, today announces a further 3 year agreement with AstraZeneca. AstraZeneca has been a major partner in the development and exploitation of BioWisdom’s Safety Intelligence Program (SIP) since the program initiation in 2007. Since then, the Safety Intelligence Program has become a key tool for predictive toxicology at AstraZeneca, and the implementation of the Program won the BioIT Best Practices award in 2009. The Safety Intelligence Program applies state-of-the-art technology and methodology to derive highly structured information from publicly accessible sources, which enables more effective searching, retrieval and analysis of prior knowledge in toxicology. The Program is used to support drug safety risk assessment at various stages of the drug discovery process. BioWisdom also applies this same technology to AstraZeneca’s own internal toxicity reports, allowing AstraZeneca scientists the best views of public and proprietary safety knowledge for compounds in both the clinical and preclinical settings. "Implementation of the Safety Intelligence Program at AstraZeneca is delivering real value in drug research and development.” said Dr David Cook, Global Safety Assessment, AstraZeneca. "Providing AstraZeneca’s scientists with desktop access to both internal and public toxicology information and knowledge is a key part of our strategies to improve the early identification and understanding of safety in our projects. Working with BioWisdom and the Safety Intelligence Program enables us to do this in a highly integrated and effective way and we look forward to continuing our strong collaboration with BioWisdom in this important area." “We are delighted that AstraZeneca has decided to continue their partnership with BioWisdom’s Safety Intelligence Program. We see this long term commitment as a testimony to the benefits that AstraZeneca has already experienced in working with us over the past three years in this program,” said Dr. Gordon Baxter, CEO. Financial terms of the agreement were not disclosed. -Ends- Notes to Editors ABOUT BIOWISDOM LTD BioWisdom delivers intelligence for the Healthcare Industry and helps clients to navigate the complex scientific and commercial issues involved in developing successful healthcare products. The company provides a powerful suite of software tools for the acquisition, integration, visualization and high value analysis of healthcare intelligence. The BioWisdom team combines extensive experience of the pharmaceutical and biotechnology industries with proven expertise in life science software development. For more information, please visit www.biowisdom.com. ABOUT ASTRAZENECA PLC AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com
CATALENT
HAMILTON Unveils ARC Sensor Technology ARC Sensors provide a robust, direct, and standard interface to an analog PLC Bonaduz, Switzerland, September 10, 2009 / b3c newswire / - HAMILTON Company, a world leader in fluid measurement, has announced the Hamilton ARC concept, a new sensor family for process control that includes pH, dissolved oxygen and conductivity measurements. More than simply sensors, ARC Sensors are the complete solution: innovative premium quality sensors with a robust, direct, and standard interface to the PLC. Hamilton ARC Sensors send an analytical signal directly to an analog process control system while delivering at the same time the power of digital sensor management. Bruno Waller, Director of Sales Laboratory and Sensors at HAMILTON comments: “With ARC Sensors process downtimes are minimized. The digital connection plus the on-board processor and memory built into every ARC Sensor means they can be pre-calibrated and configured in the lab. Due to the time-saving features for sensor operation and maintenance, costs and opportunity for human errors are drastically reduced.” Classic sensors produce weak, temperamental signals that require a separate transmitter to amplify the signal before connecting to the process control system. With ARC Sensors a technology has been developed that replaces the need for transmitters. The ARC Sensor’s built-in electronics convert the low amperage measurement signal and enables several unique sensor functions. Apart from the direct analog connectivity, ARC Sensors offer a digital connection that delivers superior data integrity, increased productivity and longer life cycles. ARC Sensors are far less prone to interruption in challenging production environments than classical sensors. ARC Sensors are available with both standard analog (4-20mA) and digital ModBus interfaces built-in and supported directly from the sensor itself. About Hamilton Company - http://www.hamiltoncompany.com/ HAMILTON is a leading worldwide supplier of precision liquid handling equipment, laboratory automation and storage systems, serving customers in academic and private research laboratories, pharmaceutical and clinical diagnostic companies and governmental institutions. HAMILTON maintains headquarters in Reno, Nevada and Bonaduz, Switzerland, both of which house R&D and production facilities. HAMILTON has subsidiaries for direct sales and service in many countries and works with a wide distributor network in other regions. HAMILTON is a privately held company. Media contact: HAMILTON Bonaduz AG Marlies Nipius Tel: + 41 81 660 67 41 E-mail: contact@hamilton.ch www.hamiltoncompany.com
